LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Listă Acțiuni・Gossamer Bio Inc

Gossamer Bio Inc

Închisă

SectorSănătate

0.15 -6.25

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

0.15

Maxim

0.16

Indicatori cheie
By Trading Economics
Venit	574K -47M
Vânzări	3.2M 17M
EPS	-0.2
Marjă de profit	-275.223
Angajați	161
EBITDA	1.2M -45M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+3225% upside

Dividende
By Dow Jones
Următoarele câștiguri	3 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-38M 41M
Deschiderea anterioară	6.4
Închiderea anterioară	0.15

Gossamer Bio Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 iun. 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 iun. 2026, 23:45 UTC

Achiziții, Fuziuni, Preluări

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 iun. 2026, 23:43 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 iun. 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 iun. 2026, 22:06 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 iun. 2026, 20:51 UTC

Câștiguri

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 iun. 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 iun. 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 iun. 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 iun. 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 iun. 2026, 18:52 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 iun. 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 iun. 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 iun. 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 iun. 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 iun. 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 iun. 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

9 iun. 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 iun. 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparație

Modificare preț

Gossamer Bio Inc Așteptări

Obiectiv de preț

By TipRanks

3225% sus

Prognoză pe 12 luni

Medie 5.32 USD 3225%

Maxim 15 USD

Minim 0.28 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGossamer Bio Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Gossamer Bio Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.